AEON vs. PULM, NXTC, CARA, TRAW, TENX, XCUR, COCP, ATHA, GOVX, and MIRA
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Pulmatrix (PULM), NextCure (NXTC), Cara Therapeutics (CARA), Traws Pharma (TRAW), Tenax Therapeutics (TENX), Exicure (XCUR), Cocrystal Pharma (COCP), Athira Pharma (ATHA), GeoVax Labs (GOVX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.
AEON Biopharma vs.
AEON Biopharma (NASDAQ:AEON) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.
22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 23.5% of AEON Biopharma shares are held by insiders. Comparatively, 0.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
AEON Biopharma has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. AEON Biopharma's return on equity of 0.00% beat Pulmatrix's return on equity.
Pulmatrix has higher revenue and earnings than AEON Biopharma. Pulmatrix is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
AEON Biopharma has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
In the previous week, AEON Biopharma had 1 more articles in the media than Pulmatrix. MarketBeat recorded 1 mentions for AEON Biopharma and 0 mentions for Pulmatrix. Pulmatrix's average media sentiment score of 1.00 beat AEON Biopharma's score of -0.18 indicating that Pulmatrix is being referred to more favorably in the news media.
Pulmatrix received 188 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 48.28% of users gave Pulmatrix an outperform vote.
AEON Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 3,146.75%. Given AEON Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe AEON Biopharma is more favorable than Pulmatrix.
Summary
AEON Biopharma beats Pulmatrix on 11 of the 17 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:AEON) was last updated on 1/20/2025 by MarketBeat.com Staff
Free AEON Stock Alerts